Hantavirus vaccine in 2026?
3% chance
- Volume
- $142.8K
- Liquidity
- $50.2K
- Ends
- Jan 1, 2027
Description
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No". The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
How it resolves
Resolution process
When the market ends, a 3 days dispute period begins. If no one disputes, rewards are distributed automatically.
- Created
- Jul 31, 2026
- Resolution date
- Jan 1, 2027